ArticleACS pharmacology & translational science2022
Trace Amine-Associated Receptor 1 (TAAR1): Molecular and Clinical Insights for the Treatment of Schizophrenia and Related Comorbidities.
Article in ACS pharmacology & translational science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 32 citations in OpenAlex.
- Structure based discovery of antipsychotic-like TAAR1 agonists.Nature communications · 2026Article
- Towards Mechanism-Informed Treatments for Mental Health.Journal of neurochemistry · 2026Review
- Metabolomic profiling and biological evaluation demonstrate the antioxidant, PPAR-γ, TAAR1, and FABP4 modulatory potential of Strelitzia species.Scientific reports · 2026Article
- Sociodemographic influences on substance use in psychosis in an African cohort.Schizophrenia research · 2025Article
- Olfactory GPCRs through the lens of structural bioinformatics.Chemical senses · 2025Review
- Neuropsychopharmacology in the era of artificial intelligence and biomolecule prediction software.NPP - digital psychiatry and neuroscience · 2025Review
- Trace Amine-associated Receptor 1: Role in the Implementation of Neuroprotective Signaling Pathways.International journal of molecular and cellular medicine · 2025Review
- p-Synephrine: an overview of physicochemical properties, toxicity, biological and pharmacological activity.EXCLI journal · 2025Review
- Molecular Mechanisms of Methamphetamine-Induced Addiction via TAAR1 Activation.Journal of medicinal chemistry · 2024Article
- Trace amine associated receptor 1: predicted effects of single nucleotide variants on structure-function in geographically diverse populations.Human genomics · 2024Article
- Discovery of a Novel Chemo-Type for TAAR1 Agonism via Molecular Modeling.Molecules (Basel, Switzerland) · 2024Article
- Unlocking the secrets of trace amine-associated receptor 1 agonists: new horizon in neuropsychiatric treatment.Frontiers in psychiatry · 2024Review
- Trace amine-associated receptor 1 agonist reduces aggression in brain serotonin-deficient tryptophan hydroxylase 2 knockout rats.Frontiers in psychiatry · 2024Article
- T1AM/TAAR1 System Reduces Inflammatory Response and β-Amyloid Toxicity in Human Microglial HMC3 Cell Line.International journal of molecular sciences · 2023Article
- Unlocking the Therapeutic Potential of Ulotaront as a Trace Amine-Associated Receptor 1 Agonist for Neuropsychiatric Disorders.Biomedicines · 2023Review
- Protein Metabolism Changes and Alterations in Behavior of Trace Amine-Associated Receptor 1 Knockout Mice Fed a High-Fructose Diet.Neurology international · 2023Article
- A growing understanding of the role of muscarinic receptors in the molecular pathology and treatment of schizophrenia.Frontiers in cellular neuroscience · 2023Review
- MUG: A mutation overview of GPCR subfamily A17 receptors.Computational and structural biotechnology journal · 2023Article
- Modelling ofFrontiers in physiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schizophrenia is a complex and severe mental illness. Current treatments for schizophrenia typically modulate dopaminergic neurotransmission by D
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.